Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IPN from our risk checks.
Ipsen S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €112.70 |
52 Week High | €128.30 |
52 Week Low | €100.50 |
Beta | 0.64 |
1 Month Change | 3.87% |
3 Month Change | 4.06% |
1 Year Change | 5.33% |
3 Year Change | 40.84% |
5 Year Change | n/a |
Change since IPO | 32.04% |
Recent News & Updates
Recent updates
Shareholder Returns
IPN | AT Pharmaceuticals | AT Market | |
---|---|---|---|
7D | 6.4% | 1.9% | -0.08% |
1Y | 5.3% | 8.7% | 2.6% |
Return vs Industry: IPN underperformed the Austrian Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: IPN exceeded the Austrian Market which returned 2.6% over the past year.
Price Volatility
IPN volatility | |
---|---|
IPN Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 4.9% |
Market Average Movement | 3.4% |
10% most volatile stocks in AT Market | 5.2% |
10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: IPN has not had significant price volatility in the past 3 months.
Volatility Over Time: IPN's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
IPN fundamental statistics | |
---|---|
Market cap | €9.33b |
Earnings (TTM) | €617.10m |
Revenue (TTM) | €3.31b |
15.1x
P/E Ratio2.8x
P/S RatioIs IPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IPN income statement (TTM) | |
---|---|
Revenue | €3.31b |
Cost of Revenue | €571.20m |
Gross Profit | €2.74b |
Other Expenses | €2.12b |
Earnings | €617.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 7.47 |
Gross Margin | 82.72% |
Net Profit Margin | 18.66% |
Debt/Equity Ratio | 9.6% |
How did IPN perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield16%
Payout RatioDoes IPN pay a reliable dividends?
See IPN dividend history and benchmarksIpsen dividend dates | |
---|---|
Ex Dividend Date | May 30 2024 |
Dividend Pay Date | Jun 03 2024 |
Days until Ex dividend | 30 days |
Days until Dividend pay date | 34 days |
Does IPN pay a reliable dividends?
See IPN dividend history and benchmarks